Details of the Drug Combination

General Information of Drug Combination (ID: DCLIWEX)

Drug Combination Name
Picoplatin SY-1425
Indication
Disease Entry Status REF
Adenocarcinoma Investigative [1]
Component Drugs Picoplatin   DM0PIY6 SY-1425   DMH8UF0
Small molecular drug N.A.
High-throughput Screening Result Testing Cell Line: HT29
Zero Interaction Potency (ZIP) Score: 3.39
Bliss Independence Score: 6.47
Loewe Additivity Score: 0.88
LHighest Single Agent (HSA) Score: 0.99

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Picoplatin
Disease Entry ICD 11 Status REF
Colorectal cancer 2B91.Z Phase 3 [2]
Ovarian cancer 2C73 Phase 3 [2]
Prostate cancer 2C82.0 Phase 3 [2]
Small-cell lung cancer 2C25.Y Phase 3 [2]
Indication(s) of SY-1425
Disease Entry ICD 11 Status REF
Acute myeloid leukaemia 2A60 Phase 1 [3]
Myelodysplastic syndrome 2A37 Phase 1 [3]
SY-1425 Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Retinoic acid receptor alpha (RARA) TTW38KT RARA_HUMAN Agonist [3]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Colon carcinoma DCUQD9C KM12 Investigative [4]
Cutaneous melanoma DCSARLZ SK-MEL-28 Investigative [1]
Melanoma DC9ZSYU SK-MEL-2 Investigative [1]
Non-small cell lung carcinoma DC4CTNN HOP-92 Investigative [1]
Ovarian serous cystadenocarcinoma DCOUEIR SK-OV-3 Investigative [1]
------------------------------------------------------------------------------------

References

1 CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125976
2 ClinicalTrials.gov (NCT00465491) Study of Picoplatin Efficacy After Relapse. U.S. National Institutes of Health.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1126165